Annual report pursuant to Section 13 and 15(d)

Equity Method Investments

v2.4.0.6
Equity Method Investments
12 Months Ended
Dec. 31, 2012
Equity Method Investments and Joint Ventures [Abstract]  
Equity Method Investments

NOTE 5 – Equity Method Investments

 

Our significant unconsolidated subsidiary that is accounted for using the equity method of accounting is our investment in BetaZone Laboratories LLC.  Summarized financial information for our investment in BetaZone Laboratories, LLC assuming 100% ownership interest is as follows:

 

    2012     2011  
Balance sheet            
Current assets     3,825       110,093  
Current Liabilities     301,864       131,672  
                 
Statement of operations                
Revenues     40,002       315,346  
Net income (loss)     (272,935 )     (102,047  

 

In 2011, when the Company’s share of losses equaled the carrying value of its investment, the equity method of accounting was suspended, and no additional losses were charged to operations. The Company’s unrecorded share of losses for 2012 totaled $122,821.